{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:13:21Z","timestamp":1784214801405,"version":"3.55.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["U01AI155299"],"award-info":[{"award-number":["U01AI155299"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UH3HL151297"],"award-info":[{"award-number":["UH3HL151297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI182159"],"award-info":[{"award-number":["R01AI182159"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jaip.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T16:13:05Z","timestamp":1756915985000},"page":"325-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging Systemic Treatments for Asthma and Allergic Diseases: New Tricks, Same Dog?"],"prefix":"10.1016","volume":"14","author":[{"given":"Alessandra","family":"Tomasello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Szefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8549-1835","authenticated-orcid":false,"given":"Katherine N.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.08.022_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2007.12.1121","article-title":"Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients","volume":"121","author":"Gober","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib5","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib7","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.08.022_bib8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib12","author":"Anderson"},{"key":"10.1016\/j.jaip.2025.08.022_bib13","author":"Carr"},{"key":"10.1016\/j.jaip.2025.08.022_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib15","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib16","author":"Whelan"},{"key":"10.1016\/j.jaip.2025.08.022_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.08.022_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100674","article-title":"Depemokimab in chronic rhinosinusitis with nasal polyps: a turning point or a missed opportunity?","volume":"6","author":"Heffler","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.jaip.2025.08.022_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12176","article-title":"Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)","volume":"12","author":"Szefler","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2025.08.022_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population","volume":"12","author":"Corren","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.08.022_bib24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/1750743X.2024.2439777","article-title":"Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)","volume":"16","author":"Szefler","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaip.2025.08.022_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.anai.2024.09.016","article-title":"Novel asthma treatments","volume":"134","author":"Seluk","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13864","article-title":"A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP \/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers","volume":"17","author":"Deiteren","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaip.2025.08.022_bib27","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1164\/rccm.202504-0841VP","article-title":"Is your placebo really needed?","volume":"211","author":"Bush","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/annrheumdis-2021-eular.1363","article-title":"AB0573 Dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study","volume":"80","author":"Nathan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2025.08.022_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2025.08.022_bib32","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib33","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fimmu.2018.01595","article-title":"Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","article-title":"TSLP, IL-33, and IL-25: not just for allergy and helminth infection","volume":"150","author":"Stanbery","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib35","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/IAI.02908-14","article-title":"Crucial and diverse role of the interleukin-33\/ST2 axis in infectious diseases","volume":"83","author":"Rostan","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaip.2025.08.022_bib36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.1215418","article-title":"The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses","volume":"335","author":"Bonilla","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jaip.2025.08.022_bib37","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1073\/pnas.1418549112","article-title":"T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses","volume":"112","author":"Baumann","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jaip.2025.08.022_bib38","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib39","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib40","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.08.022_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib43","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib44","article-title":"A multiple ascending-dose study with verekitug, a novel antibody to the human thymic stromal lymphopoietin receptor, in adults with asthma","volume":"209","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib45","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13874","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: results from two terminated phase II trials","volume":"17","author":"Kosloski","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaip.2025.08.022_bib47","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1111\/bcp.16195","article-title":"Population pharmacokinetic\/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease","volume":"90","author":"Sadiq","year":"2024","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.jaip.2025.08.022_bib48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/cpt.3147","article-title":"A randomized phase I study of the anti-interleukin-33 antibody tozorakimab in healthy adults and patients with chronic obstructive pulmonary disease","volume":"115","author":"Reid","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2025.08.022_bib49","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/jpet.121.000686","article-title":"ASP7266, a novel antibody against human thymic stromal lymphopoietin receptor for the treatment of allergic diseases","volume":"380","author":"Numazaki","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaip.2025.08.022_bib52","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/jpm11040240","article-title":"Systems approaches to treatment response to imatinib in severe asthma: a pilot study","volume":"11","author":"Baek","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib54","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","article-title":"Targeting alarmins in asthma: from bench to clinic","volume":"155","author":"Akenroye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib55","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33\u2013producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaip.2025.08.022_bib56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1165\/rcmb.2018-0402OC","article-title":"Cigarette smoke triggers IL-33\u2013associated inflammation in a model of late-stage chronic obstructive pulmonary disease","volume":"61","author":"Lee","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaip.2025.08.022_bib57","first-page":"A65","article-title":"S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma","volume":"79","author":"Corren","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2025.08.022_bib58","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jaip.2025.08.022_bib59","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2023.05.014","article-title":"Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE): a randomized controlled trial","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib60","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib61","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/JAA.S337284","article-title":"Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial","volume":"15","author":"Davidescu","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaip.2025.08.022_bib62","article-title":"Efficacy and safety of rilzabrutinib\u2014a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study","volume":"209","author":"Laidlaw","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib63","first-page":"AB373","article-title":"Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU phase 2 dose-ranging study","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib64","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib66","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jaci.2022.02.025","article-title":"Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission","volume":"149","author":"Ben-Baruch Morgenstern","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib67","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.08.022_bib68","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2017.11.043","article-title":"Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo","volume":"142","author":"Toki","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib69","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1111\/all.14879","article-title":"Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice","volume":"76","author":"Toki","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.08.022_bib70","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaci.2018.01.053","article-title":"Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus\u2013induced type 2 responses and immunopathology","volume":"142","author":"Bloodworth","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1164\/rccm.202004-0993OC","article-title":"Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists","volume":"203","author":"Foer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamainternmed.2024.5982","article-title":"Association of antidiabetic medication and asthma attacks: self-controlled case series and population-based cohort","volume":"185","author":"Lee","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib73","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1513\/AnnalsATS.201812-897OC","article-title":"Association of metformin initiation and risk of asthma exacerbation. A claims-based cohort study","volume":"16","author":"Wu","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2025.08.022_bib74","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/resp.12818","article-title":"Metformin use and asthma outcomes among patients with concurrent asthma and diabetes","volume":"21","author":"Li","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2025.08.022_bib75","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5235","article-title":"Early phase double-blind, placebo-controlled study of medium chain triglycerides additive in adult asthma","volume":"211","author":"Comhair","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/BTT.S511125","article-title":"OX40\/OX40L as a therapeutic target in atopic dermatitis: a scoping review","volume":"19","author":"Valenzuela","year":"2025","journal-title":"Biologics Targets Ther"},{"key":"10.1016\/j.jaip.2025.08.022_bib77","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","article-title":"Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes","volume":"208","author":"Foer","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2025.08.022_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071380","article-title":"Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study","volume":"379","author":"Pradhan","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2025.08.022_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334006","article-title":"Mitochondria: the gatekeepers between metabolism and immunity","volume":"15","author":"Trinchese","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2025.08.022_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41420-025-02403-1","article-title":"Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives","volume":"11","author":"Shi","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jaip.2025.08.022_bib81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10565-024-09928-8","article-title":"Multifaceted roles of mitochondria in asthma","volume":"40","author":"Zhang","year":"2024","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.jaip.2025.08.022_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1186317","article-title":"Mitochondria dysfunction in airway epithelial cells is associated with type 2-low asthma","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.jaip.2025.08.022_bib83","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","article-title":"PrecISE: precision medicine in severe asthma: an adaptive platform trial with biomarker ascertainment","volume":"147","author":"Israel","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825008232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825008232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:36:35Z","timestamp":1780126595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825008232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2213219825008232"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.08.022","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Systemic Treatments for Asthma and Allergic Diseases: New Tricks, Same Dog?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}